CM
ASBPW

Cohanzick Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Cohanzick Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-166,667
Closed – – 30
2023
Q4 		$0 Hold
166,667
– – ﹤0.01% 67
2023
Q3 		$0 Hold
166,667
– – ﹤0.01% 59
2023
Q2 		$0 Hold
166,667
– – ﹤0.01% 69
2023
Q1 		$6.97K Buy
+166,667
New +$11K 0.01% 90
2022
Q3 		– Sell
-18,383
Closed -$3K – 311
2022
Q2 		$3K Buy
+18,383
New +$4K ﹤0.01% 363

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Cohanzick Management's ASBPW Position: Q1 2024 in Review

Cohanzick Management sold out of Aspire Biopharma Warrant (ASBPW) in Q1 2024, closing a stake of 166,667 shares.

Cohanzick Management first reported a position in ASBPW in Q2 2022 and held it in 5 quarters. The position peaked at $6.97K in Q1 2023. 34 funds tracked by Wall St. Rank hold ASBPW as of Q1 2024.

  • Cohanzick Management reported no remaining Aspire Biopharma Warrant position as of Q1 2024 after selling out during the quarter.
  • Cohanzick Management sold 166,667 Aspire Biopharma Warrant shares in Q1 2024.
  • Cohanzick Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 5 quarters.
  • Cohanzick Management's Aspire Biopharma Warrant position peaked at $6.97K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2024.

Based on Cohanzick Management's 13F filing for Q1 2024, filed 14 May 2024.